3 Health Care Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 76 points (-0.4%) at 18,051 as of Friday, May 29, 2015, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,058 issues advancing vs. 1,892 declining with 171 unchanged.

The Health Care sector currently sits up 0.7% versus the S&P 500, which is down 0.3%. Top gainers within the sector include Alnylam Pharmaceuticals ( ALNY), up 3.6%, Eli Lilly and ( LLY), up 3.0%, Mylan ( MYL), up 1.3% and Regeneron Pharmaceuticals ( REGN), up 0.7%. On the negative front, top decliners within the sector include Sanofi ( SNY), down 2.4%, AstraZeneca ( AZN), down 2.0%, Novo Nordisk A/S ( NVO), down 1.5%, Novartis ( NVS), down 1.2% and Valeant Pharmaceuticals International ( VRX), down 1.1%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Incyte ( INCY) is one of the companies pushing the Health Care sector higher today. As of noon trading, Incyte is up $2.59 (2.4%) to $110.73 on average volume. Thus far, 472,051 shares of Incyte exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $107.06-$110.90 after having opened the day at $107.90 as compared to the previous trading day's close of $108.14.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. Incyte has a market cap of $19.3 billion and is part of the drugs industry. Shares are up 47.9% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts who rate Incyte a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Incyte as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Incyte Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Endo International ( ENDP) is up $1.76 (2.1%) to $84.70 on average volume. Thus far, 1.8 million shares of Endo International exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $83.68-$85.28 after having opened the day at $84.45 as compared to the previous trading day's close of $82.94.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Endo International has a market cap of $14.9 billion and is part of the drugs industry. Shares are up 15.0% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts who rate Endo International a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Endo International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Endo International Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Pfizer ( PFE) is up $0.50 (1.5%) to $34.94 on average volume. Thus far, 18.7 million shares of Pfizer exchanged hands as compared to its average daily volume of 26.0 million shares. The stock has ranged in price between $34.41-$34.96 after having opened the day at $34.48 as compared to the previous trading day's close of $34.44.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $211.2 billion and is part of the drugs industry. Shares are up 10.6% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Pfizer Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

If you liked this article you might like

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round

Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round

Playing Defense and Offense: Cramer's 'Mad Money' Recap (Tuesday 11/7/17)

Playing Defense and Offense: Cramer's 'Mad Money' Recap (Tuesday 11/7/17)

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers